Highly Accurate Diagnosis of Pleural Tuberculosis by Immunological Analysis of the Pleural Effusion by Sutherland, Jayne S. et al.
Highly Accurate Diagnosis of Pleural Tuberculosis by
Immunological Analysis of the Pleural Effusion
Jayne S. Sutherland*, Danlani Garba, Augustin E. Fombah, Awa Mendy-Gomez, Francis S. Mendy, Martin
Antonio, John Townend, Readon C. Ideh, Tumani Corrah, Martin O. C. Ota
Medical Research Council Unit, Atlantic Road, Fajara, The Gambia, West Africa
Abstract
PleuralTBisnotoriouslydifficulttodiagnoseduetoitspaucibacillarynatureyetitisthemostcommoncauseofpleuraleffusions
inTBendemic countriessuchasTheGambia. Weidentified bothcellular andsoluble biomarkersinthe pleuralfluidthatallowed
highly accurate diagnosis of pleural TB compared to peripheral blood markers. Multi-plex cytokine analysis on unstimulated
pleural fluid showed that IP-10 resulted in a positive likelihood ratio (LR) of 9.6 versus 2.8 for IFN-c; a combination of IP-10, IL-6
and IL-10 resulted in an AUC of 0.96 and positive LR of 10. A striking finding was the significantly higher proportion of PPD-
specific IFN-c+TNF-a+ cell population (PPD-IGTA) in the pleural fluid compared to peripheral blood of TB subjects. Presence of
this pleural PPD-IGTA population resulted in 95% correct classification of pleural TB disease with a sensitivity of 95% and
specificity of 100%. These data suggest that analysis of the site of infection provides superior diagnostic accuracy compared to
peripheral blood for pleural TB, likely due to the sequestration of effector cells at this acute stage of disease.
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Introduction
Tuberculosis (TB) still remains one of the top three deadly
diseases in developing countries with 1.7 million deaths recorded in
2009 [1]. While effective treatment is available, this relies on early
and accurate diagnosis. To date, sputum smear (which is unreliable,
particularly in HIV-positive and extrapulmonary TB) and sputum
culture (which is time-consuming and expensive) remain the ‘gold-
standard’ techniques for diagnosis of TB. Development of point-of-
care diagnostics will have vast public health benefits by decreasing
morbidity and mortality and reducing transmission rates of TB but
this requires determination of biomarkers with high specificity and
sensitivity for active TB disease.
Tuberculosis is the most common cause of pleural effusion in
developing countries but it is notoriously difficult to diagnose due
to its paucibacillary nature: positive cultures are seen in less than
25% of HIV-negative cases but can rise to 75% with HIV-
infection [2]. Host immune factors provide greater diagnostic
accuracy, including levels of IFN-c and Adenosine Deaminase
(ADA) [3], both of which have .95% specificity and sensitivity,
appear to be unaffected by HIV co-infection and do not require
any sample preparation [3–7]. However these markers are less
definitive in TB-endemic countries and have not been evaluated in
a West African cohort.
Tuberculosis infection occurs by inhalation of Mycobacterium
tuberculosis (MTb) bacilli. These reside within lung macrophages and
can be contained (but rarely eliminated) at early stages of infection:
thus close to 2 billion people world-wide are infected with MTb and
10% of these will progress to active disease in their lifetime [1].
Progression to active disease occurs due to changes in bacterial
virulence and/or the host immune system: the prime example
shown with con-current HIV infection, which is the most potent
known risk factor for progression to active tuberculosis [8]. The fact
that the localised immune response is occurring in the lung suggests
that analysis of the peripheral blood may not be representative of
the host immune response, particularly at the acute stage of disease.
Indeed, there is extensive literature showing sequestration of
immune cells to the lung during TB [9–13], although their role
appears to depend on the type and stage of disease [13].
In this study we analysed paired blood and pleural fluid samples
from patients presenting with pleural effusion who were
subsequently classified as having TB or not (malignancy,
pneumonia, liver disease). The cellular and soluble profiles of
the pleural fluid easily discriminated between subjects with TB and
those without and should be further validated as tools for new and
improved TB diagnostics.
Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Ethical approval was obtained from
the Gambia Government/Medical Research Council (MRC) Joint
Ethics Committee. All patients provided written informed consent
for the collection of samples and subsequent analysis.
Subjects
Subjects were included in this study if they were above 15 years
of age and were seen at the TB clinic, general outpatient’s clinic or
admitted to the ward at MRC, Fajara with evidence of pleural
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50 mL of pleural fluid (PF) and 5 mL of peripheral blood (PB) was
taken for immunological analysis. Pleural fluid and sputum (where
possible) were sent to the microbiology lab for routine smear and
Bactec culture. A sample of pleural fluid was also sent to the
biochemistry lab for assessment of glucose and protein levels. HIV
testing was performed on all consenting patients. We also
performed Mantoux skin test reactivity (2 IU PPD, SSI, Den-
mark). 200 mL of PB was used to obtain differential cell counts
using a Medonic haematology analyser (Merck).
Classification of subjects presenting with pleural effusion
Subjects were classified as having TB if they had an exudative
effusion (for this study, exudative effusion was classified as pleural
protein .30 g/L and glucose ,4 mM) and were bacteriologically
culture positive (definite TB) or had a good response to TB
treatment and had ADA levels .35 IU/mL and a lymphocytic
infiltrate (.75% of PF cells) (probable TB; Table 1). Out of 41
subjects with evaluable data, 7 were confirmed TB by bacterial
culture; 23 were classified as having probable TB and 11 were
classified as ‘not TB’. Of these, 3 had liver disease (cirrhosis), 5 had
pneumonia (Streptococcus pneumoniae), 2 had a malignancy and 1 was
unclassified. Two subjects (19 and 21) had extremely high ADA
levels; previously been shown to be indicative of empyema [7].
Subject 19 was however culture positive and thus classified as
having TB disease while subject 21 was diagnosed radiologically
and clinically with pneumonia. Subject 26 had extremely low
ADA levels and had a final classification of Cirrhosis. While most
of the effusions were lymphocytic, subject 12 had the lowest
percentage (15%) and was diagnosed with pneumonia. This
patient also had a high peripheral blood WBC count (10.8E
9/L)
with a granulocyte to lymphocyte ratio of 8.3, which we have
previously shown to be indicative of pneumonia rather than TB
[14]. 9 subjects were HIV-positive of which 7 were subjects with a
classification of TB (4 were culture positive=definite TB and 3
were classified according to ADA levels and response to
treatment=probable TB) and 2 with a classification of pneumo-
nia. Subject 6 was Mtb culture positive and had immune
reconstitution inflammatory syndrome (IRIS) after initiation of
anti-retroviral treatment.
Pleural fluid processing
Fresh PF samples were centrifuged at 600gmax for 5 min. at
room temperature (RT). 261.5 mL aliquots of fluid were stored at
220uC for later analysis of ADA and cytokine levels. The
remaining cell pellet was resuspended in 5 mL of RPMI+10%
FCS from which cell number and viability were determined using
Trypan blue exclusion.
Flow Cytometry
Approximately 1 million PF cells or 200 mL of PB was used for
each test of a flow cytometry panel which all contained anti-FcR
block at a final concentration of 1:10. Ex vivo staining involved
incubation with 20 mL of previously titrated antibody cocktails.
Antibodies were purchased from Becton-Dickinson (USA) unless
otherwise stated and included CD4-APC-Al750 (APCA;
ebioscience, UK); CD8-Pacific Blue (PB), CD45RO-PECy5
(PC5), CD28-FITC, CD27-APC, CCR7-PE and CD62L-PECy7
(PC7; both from ebioscience, UK) for detection of naı ¨ve and
memory T cell phenotypes; Va24-FITC, Vb11-PE (both from
Dako, Denmark), CD4-PerCP (PCP), CD127 Allexa-647
(ebioscience, UK), CD25-PC7 (ebioscience, UK) and CD8-PB
for detection of T regulatory cell phenotypes; CD209-FITC
(ebioscience, UK), HLA-DR-PE, CD11c-PC5, CD14-APC,
CD123-PC7 (ebioscience, UK), CD11b-APCCy7 (ebioscience,
UK) and CD8-PB for detection of innate cells; cdTCR-APC,
abTCR-FITC, CD3-PC7, CD8-PB, CD4-PerCP, CD56-PE and
CD19-APCA (ebioscience, UK) for detection of ab T cells, cd T
cells, B and NK cells and Ki67-FITC, Perforin-PE, CD38-PC7
(ebioscience, UK), CD4-PCP, CD56-APC and CD8-PB for
analysis of the functional status of the ex vivo cells. After 30 min.
incubation at RT in the dark, 2 mL of FACS lysing buffer was
added (Becton-Dickinson, USA) and cells incubated for a further
9 minutes. Tubes were then centrifuged (600gmax, 5 minutes),
supernatant poured off, 16wash in FACS buffer (PBS/FCS/Az)
performed and finally resuspended in 300 mL of FACS buffer for
flow cytometry acquisition.
Intracellular cytokine analysis
Overnight antigenic stimulation. One million PF cells in
200 mL or 200 mL of PB was used for each test of an intracellular
cytokine assay. Cells were stimulated with ESAT-6/CFP-10 fusion
protein (10 mg/mL), PPD (10 mg/mL), or anti-CD3 (10 mg/mL).
The negative control tube was incubated without antigen. Co-
stimulation with anti-CD28 and anti-CD49d (Becton-Dickinson,
USA) was added to all tubes (final concentration 2 mg/mL each).
Tubes were vortexed and incubated for 2 hours. Brefeldin A was
then added (final concentration 10 mg/mL), tubes vortexed,
covered and incubated overnight (16 h) at 37uC, 5% CO2.
Antibody staining
20 mL of antibody cocktail (CD45RO-PC5, CD27-FITC, CD8-
PB (all from Becton-Dickinson, USA) and CD4-APCAl750
(ebioscience, UK) was added to each tube and incubated for
30 min at RT, in the dark. Red blood cells were lysed by addition
of 2 mL FACS lysing buffer for 9 min followed by centrifugation
at 600gmax for 5 min. Supernatant was poured off and cells
resuspended in 500 mL of 1X FACS Perm 2 solution (Becton-
Dickinson, USA). Tubes were vortexed and incubated for a further
20 min, at RT, in the dark. Tubes were then centrifuged at
620gmax, supernatant removed and 20 mL of cytokine cocktail
(TNF-a-PC7 at 1:80 (ebioscience, UK), IFN-c-APC at 1:40 and
IL2-PE at 1:80 (both from Becton-Dickinson, USA) added. Cells
were incubated for 30 min, RT, in the dark, washed by addition of
1 mL FACS buffer and centrifuged at 620gmax for 5 min. Finally,
cells were resuspended in 300 mL FACS buffer for acquisition.
Flow cytometry acquisition and analysis
Cells were acquired using a CyAn ADP
TM 9-colour flow
cytometer (Beckman Coulter, USA). Lymphocytes were gated
according to 90u FSC and SSC and compensation performed. For
ex vivo staining, 100,000 lymphocytes were acquired and 200–
500,000 were acquired for intracellular cytokine staining. Analysis
was performed using FlowJo software version 9.2 (Treestar, USA).
Analysis and presentation of distributions was performed using
SPICE version 5.1, downloaded from http://exon.niaid.nih.gov/
spice [15]. Comparison of distributions was performed using a
Student’s T test and a partial permutation test as described [15].
Adenosine Deaminase (ADA) assay
To assess ADA levels in the pleural fluid we adapted the
standard Galanti and Giusti protocol [7] according to the
manufacturer’s instructions (Diazyme, USA). Briefly, the high
control provided with the kit was serially diluted to form a
standard curve ranging from 145.2624.7 to 4.560.8 IU/L. 5 mL
of samples, standards, low control (31.465.3 IU/L) and calibrator
(50 IU/L) were added to 180 mL of R1 (PNP) in duplicate in a flat-
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37uC for 5 min then 90 mL of R2 (XOD) was added to each well.
Samples were incubated at RT and read on an ELISA plate
reader (Multiscan, Labsystems, Finland) at 550 nm after 3 min.
Data were analysed using Softmax Pro software (Molecular
Devices, USA). A standard curve was constructed using the
diluted high standard, the calibrator concentration was deter-
mined and results were adjusted accordingly. All samples were
read in duplicate and mean values (IU/L) determined. This assay
is specific for ADA, has no detectable reaction with other
nucleosides and is not affected by serum bilirubin up to 20 mg/
dL, hemoglobin up to 200 mg/dL, triglycerides up to 750 mg/dL,
Table 1. Subject information and classification.
Subject PF ADA PF %L Culture Exudate TST HIV Tx Response Classification
1 n/d 88 neg yes pos neg improved Probable TB
2 55 87 neg yes pos neg improved Probable TB
3 39 95 neg yes n/d neg improved Probable TB
4 51 81 neg yes pos neg improved Probable TB
5 110 45 neg yes neg pos not given Pneumonia
6 41 91 pos yes n/d pos improved Definite TB
7 47 86 neg yes pos neg improved Probable TB
8 45 73 neg yes pos neg improved Probable TB
9 24 89 neg yes n/d neg not given Cirrhosis
10 59 36 pos yes neg pos died Definite TB
11 29 15 neg yes n/d neg died Pneumonia
12 45 94 neg yes pos neg improved Probable TB
13 58 n/d neg yes neg pos improved Probable TB
14 33 86 pos yes pos pos improved Definite TB
15 45 93 n/d yes pos neg improved Probable TB
16 29 94 neg yes neg neg died Probable TB
17 16 77 n/d yes neg neg improved Probable TB
18 58 62 pos yes n/d neg improved Definite TB
19 689 65 pos yes pos neg improved Definite TB
20 52 34 pos yes pos neg improved Definite TB
21 1463 40 neg yes neg neg not given Pneumonia
22 38 46 neg yes pos neg improved Probable TB
23 n/d 39 neg yes neg n/d not given Malignancy
24 39 84 neg yes neg pos improved Probable TB
25 26 91 neg yes pos neg improved Probable TB
26 0.82 84 neg no neg neg not given Cirrhosis
27 45 83 neg yes pos neg improved Probable TB
28 37 93 neg yes pos neg not given Pneumonia
29 15 28 neg yes neg neg died Probable TB
30 47 85 neg yes pos pos not given Pneumonia
31 9 91 n/d yes neg neg not given Malignancy
32 57 71 neg yes n/d neg improved Probable TB
33 30 85 neg yes n/d neg not given Unknown
34 6 88 neg yes neg neg improved Probable TB
35 71 82 pos yes neg pos improved Definite TB
36 39 n/d neg yes pos neg improved Probable TB
37 54 96 neg yes pos neg improved Probable TB
38 59 34 neg yes neg pos Improved Probable TB
39 0 n/d neg no neg n/d not given Cirrhosis
40 24 74 neg yes pos neg improved Probable TB
41 68 85 n/d yes neg neg Improved Probable TB
ADA=Adenosine Deaminase; n/d=not done; TST=Tuberculin skin test; PF=pleural fluid; %L=% lymphocytes; Exudate=PF protein .30 g/L and glucose .3.3 mmol/
L; pos=positive; neg=negative; HIV=Human Immunodeficiency Virus; Culture=bacteriological culture of sputum or pleural fluid; Tx=treatment.
doi:10.1371/journal.pone.0030324.t001
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indicative of TB in lymphocyte-predominant pleural fluid [7].
27-plex cytokine analysis of unstimulated pleural fluid
A 27-plex cytokine-bead kit was used (Bio-Rad, USA) and the
assay performed according to the manufacturer’s instructions.
Cytokines, chemokines and growth factors assessed were: IL-1b,
IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-0, IL-10, IL-12(p70),
IL-13, IL-15, IL-17, Eotaxin, FGF, G-CSF, GM-CSF, IFN-c,I P -
10, MCP-1, MIP-1a,M I P - 1 b, PDGF-BB, RANTES, TNF-a and
VEGF. Following pre-wetting of the filter plate, 50 ml of bead
suspension was added to each well and washed twice. 50 mlo f
samples and standards were then added, the plate was sealed and
shaken for 30 sec at 1100 rpm, and incubated for 30 min at
300 rpm. The plate was washed 3 times then 25 ml of pre-diluted
detection antibody was added. Following shaking, the plate was
incubated for 30 min at 300 rpm in the dark. After washing,
50 ml of 1X streptavidin-PE was added to each well and
incubated for 10 min. The plate was again washed and
resuspended in 125 ml of assay buffer, sealed, mixed and
immediately read on the Bioplex analyser using Bioplex manager
software (version 4.0; Bio-Rad, USA) and a low PMT setting. All
standards were run in duplicate.
Statistical analyses
Data were analysed by Wilcoxon matched pairs test, Kruskal-
Wallis test with Dunn’s post-test comparison, Mann-Whitney U-
test or multiple logistic regression analysis. Immunological analyses
were performed on all subjects (HIV-positive and negative) and
also on HIV-negative alone and we found no statistical difference.
As such, all subjects are grouped together unless otherwise
indicated. Furthermore, following validation with the TB-definite
subjects, all subjects with probable or definite TB were grouped
together for statistical purposes.
Results
The immune cell profile of the peripheral blood is
significantly different to the site of infection in pleural TB
We analysed the cellular content of the PF and compared this
to the PB for each subject. Analysis of the lymphocyte and CD4+
T cell proportions in the PF indicated a likelihood of TB
(Fig. 1a). Subject 11 was classified with Streptococcus Pneumoniae
infection and had a granulocytic effusion (90%) whereas Subject
6, classified with TB (culture-confirmed) had a lymphocytic
infiltrate. Furthermore, only 4.6% of the lymphocytes were CD4+
in Subject 11 compared to 58.7% in Subject 6 (Fig. 1a). Flow
cytometry also allowed us to determine other underlying causes of
the effusion, particularly malignancy and showed distinct
differences between the blood and PF profiles. For example,
assessment of the lymphocyte population for subject 33 showed
normal blood levels of CD3+ T cells but elevated B cell levels
(22%; Fig. 1b) and in the pleural fluid they had only 0.8% CD3+
T cells but 97% B cells (Fig. 1b). Flow cytometry of an ascites
sample was also performed although this was not included in the
statistical analysis. The ascites profile again was very distinct to
that seen in the peripheral blood. The blood had a large
Va24+CD4+ proportion which was not present in the ascites
(Fig. 1c). This patient was subsequently confirmed to have both
TB and lymphoma.
Comparison between the PB and the PF for each patient was
performed using a Wilcoxon matched-pairs test (Table 2). There
was a significantly higher proportion of CD3+ T cells in the PF
compared to the PB (median[IQR]=72[43–80] for PF and
44[33–51] for PB; p=0.0045) which was due to an increase in
CD4+ T cells but not CD8+ T cells (p=0.0001 for CD4+ T cells;
Table 2), resulting in an increased ratio of CD4:CD8 T cells
(p=0.0001). Further classification of the CD4+ T cells based on
CD27 and CD45RO expression showed a significant decrease in
the proportion of naı ¨ve cells (CD27+CD45RO2) but increase in
central memory (CM) cells (CD27+CD45RO+) (p=0.0004 and
p=0.0166 respectively; Table 2) in the PF compared to PB.
Although the overall CD8+ T cell proportion was similar between
the PF and PB, there was a significantly higher proportion of naı ¨ve
CD8+ cells and lower proportion of CD8+ terminal effector (TE;
CD272CD45RO2) cells (p=0.0173 and p=0.0005 respectively;
Table 2) in the PF. There was also an increased expression of
CD127 (IL7Ra) on both the CD4+ and CD8+ cells (p=0.0175
and p=0.0005 respectively) in the PF compared to the PB.
Increased expression of the activation marker, CD38, was also
seen on the CD4+ T cells in the PF compared to the PB
(median[IQR]=6.3[4.0–15] for PF compared to 2.2[1.4–9.4] for
PB (p=0.0143; Table 2).
The proportion of CD56+ NK cells was significantly lower in the
PF compared to the PB (median[IQR]=2.5[1.6–4.6] and 8.6[4.6–
13] respectively; p=0.0001) but there was no difference in the
proportion of B cells, cd T cells, NKT cells or CD14+ monocytes.
The proportion of CD4+CD25+ and CD4+CD25+CD127
lo T
regulatory (Treg) cells were both significantly higher in the PF
compared to the PB (p=0.0016 and p=0.0002 respectively).
However, the ratio of Treg/Teff cells did not change (median 4.6 for
PB and 4.9 for PF; Table 2).
We next compared the PB subsets of TB and non-TB patients in
order to see if PB markers could be used as a surrogate for pleural
TB (Table 2). Interestingly, the proportion of CD4+ T cells was
similar in TB and non-TB subjects in the blood (media-
n[IQR]=26[21–32] for TB and 22[15–27] for non-TB) but there
was a significantly lower CD4:CD8 ratio in TB patients
(median=1.6 for TB and 2.7 for non-TB; p=0.0192) due to a
higher (but not significant) proportion of CD8+ T cells
(median[IQR]=16[11–24] for TB and 8.4[4.8–17] for non-TB;
Table 2). We also saw a significantly higher level of CD56+ NK
cells in the PB of TB patients (median[IQR]=8.6[4.6–13]
compared to 5.3[3.5–9.0] for non-TB; p=0.0296; Table 2).
We did not see any differences in the total WBC levels,
granulocyte, lymphocyte proportions (or ratio), MCV, hematocrit,
hemoglobin or platelet levels (data not shown) between TB and
non-TB subjects.
We next compared the PF subsets between TB and non-TB
patients and found an increase in CD8+ T cells (media-
n[IQR]=17[12–23] for TB and 10[0.9–16] for non-TB
(p=0.0099)) but no difference in the proportion of CD4+ T
cells (Table 2). However, within the CD4+ subset, there was a
shift to a central memory phenotype with a median of 49% in TB
compared to 23% in non-TB subjects (p=0.0048). Despite the
increase in proportion of CD8+ T cells, no difference in the
proportions of naı ¨ve and memory subsets within the CD8+ Tc e l l
population was observed (Table 2). There was a 4-fold increase
in the proportion of Treg cells in the pleural fluid of TB patients
(p=0.0291) but again no difference in the ratio of Treg to Teff
cells (Table 2). We also saw a significantly increased expression
of CD38 on both the CD4+ (median%=6.3 for TB and 2.4 for
non-TB) and CD56+ cells (median%=17 for TB and 4.1 for
non-TB) (p=0.0065 and p=0.0031 respectively; Table 2).
However, we saw no difference in the proportion of Ki-67 or
perforin positive cells within the CD4+,C D 8 + or CD56+ subsets
(data not shown).
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30324Figure 1. Flow cytometry comparison between peripheral blood and pleural fluid. (a) Ex vivo assessment of the cell phenotypes within the
pleural fluid. Shown are representative flow cytometry profiles from a patient with pneumonia and one who was diagnosed with TB. Profiles are first
gated on the lymphocyte population as determined by FSC and SSC. Following singlet and CD3 gating, analysis of CD4+ and CD8+ T cell populations
is performed. (b) Analysis of a subject with pleural effusion caused by malignancy. In this case CD3 and CD19 are plotted together to illustrate T and B
cell proportions in the blood (left) and pleural fluid (right) of a subject with a malignancy (subject 33). (c) Flow cytometry profile from blood and
ascites where the blood had a distinct Va24+CD4+ T cell population; absent from the ascites. (d) Functional analysis of PF cells. Overnight stimulation
of PF cells with PPD was followed by intracellular cytokine detection. Following gating on the CD4+ T cells, TNF-a and IFN-c positive cells were
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stimuli are significantly higher in the PF compared to PB
The function of pleural and blood lymphocytes was evaluated
by intracellular cytokine detection following overnight stimulation
with TB-specific antigens (PPD and ESAT-6/CFP-10 (EC)) or
positive control (aCD3/CD28 stimulation). Subjects classified with
TB (probable or definite) had a distinct population of IFN-c+TNF-
a+ (IGTA) double-positive cells in the PF following stimulation
with PPD and EC at much higher levels than the peripheral blood
(Fig. 1d red box; Fig. 2a). Analysis of the PPD-IGTA population
in the pleural fluid identified pleural TB with a sensitivity of 95%
(95%CI=75–100) and specificity of 100% (95%CI=63–100) and
was never seen in patients who did not have TB (negative
predictive value of 100%). The memory phenotype of the IGTA
population was also assessed based on CD27 and CD45RO
expression (Figs. 1e and 1f). As expected, the majority of the
responding cells were of an effector memory phenotype
(CD272CD45RO+; Figs. 1e and 1f) compared to naı ¨ve
(CD27+CD45RO2) or central memory (CD27+CD45RO+)
cells (p,0.001). Unexpectedly, the response in the PB was
magnitudes lower than in the PF, even for the positive control
stimulation (Fig. 2a). Furthermore, the quality of the response was
also significantly different. Analysis of total IFN-c,T N F - a or IL-2
producing cells showed a highly significant increase in the
proportion of CD4+IFN-c+ and CD4+TNF-a+ cells in TB
patients compared to non-TB (p=0.0124 and p=0.0060
respectively; Fig. 2b). Analysis of the combinatorial responses
showed a significant increase in the proportion of triple positive
(IFN-c+IL-2+TNF-a+) and double positive (TNF-a+IFN-c+) cells
in TB compared to non-TB patients following both PPD and EC
stimulation (p=0.0011 and p,0.0001 respectively; Figs. 2c and
2d). This was only seen in the PF and not the PB where the
majority of responses were single-positive cytokines (Figs. 2c
and 2d).
assessed. There was no response from the patient with a bacterial infection but a striking response from the patients with definite and probable TB. In
particular, note the presence of a distinct IFN-c+TNF-a+ double-positive cell population (IGTA; red box). (e) The CD4+ IGTA population was gated and
the naı ¨ve/memory phenotype determined by CD27 and CD45RO expression (red-dot overlay). (f) Analysis of 12 subjects with evaluable data was
performed using a Kruskal-Wallis test followed by Dunn’s post-test comparison. We found the majority of the IGTA+ cells were of an effector memory
phenotype (EM; CD272CD45RO+), bottom right quadrant of (d). N=naı ¨ve (CD27+CD45RO2); CM=central memory (CD27+CD45RO+); EM=effector
memory (CD272CD45RO+) and TE=terminal effectors (CD272CD45RO2).
doi:10.1371/journal.pone.0030324.g001
Table 2. Comparison of immune subsets in peripheral blood and pleural fluid of TB and non-TB patients.
TB (n=30) non-TB (n=11) TB PF vs PB PF TB vs no TB
Subset (%) PB PF PB PF p-value p-value
CD3 44[33–51] 72[43–80] 36[7.3–52] 64[1.2–82] 0.0045 0.7168
CD4 26[21–33] 45[33–61] 22[15–27] 34[2.7–63] 0.0001 0.2147
CD8 16[11–24] 17[12–23] 8.4[4.8–17] 10[0.9–16] 0.8092 0.0099
4/8 ratio 1.5[0.9–2.1] 3.4[1.5–5.0] 2.7[1.6–4.8] 2.4[1.4–5.6] 0.0001 0.7145
CD19 8.2[2.5–12.4] 3.9[1.1–10] 4.6[1.2–13] 6.0[2.3–7.3] 0.0691 0.8057
CD56 8.6[4.6–13] 2.5[1.6–4.6] 5.3[3.5–10] 1.0[0.1–4.7] 0.0001 0.0813
cdTCR 3.0[0.8–3.7] 1.5[1.0–2.8] 1.8[1.2–6.6] 2.1[0.4–3.0] 0.5230 0.8176
CD14 7.9[4.5–12] 2.2[0.8–7.3] 7.2[2.6–14] 3.3[0.5–15] 0.2673 0.6323
CD11b
+CD11c
+ 2.5[0.8–7.5] 1.6[0.5–6.1] 4.0[1.0–8.6] 0.5[0.1–5.3] 0.7937 0.3690
CD4
+CD25
+ 1.4[0.8–2.4] 2.8[1.8–4.2] 0.9[0.3–1.9] 0.7[0.1–3.6] 0.0016 0.0579
Tregs 1.0[0.4–1.5] 2.3[1.4–3.1] 0.6[0.2–1.0] 0.5[0.0–2.3] 0.0002 0.0291
Tregs/Teff 4.6[2.6–6.8] 4.9[2.9–8.0] 2.9[1.3–5.4] 3.5[0.4–7.6] 0.5774 0.3571
CD4 N 36[25–53] 21[12–37] 55[29–63] 19[4.8–52] 0.0004 0.8486
CD4 CM 27[15–42] 49[30–63] 25[14–31] 24[0.3–34] 0.0166 0.0048
CD4 EM 15[6.1–24] 13[4.5–20] 9.0[5.6–25] 8.0[0.3–22] 0.6158 0.2327
CD4 TE 7.8[5.3–11] 3.9[2.3–5.4] 8.1[6.4–21] 11[1.6–29] 0.1485 0.4839
CD8 N 34[21–54] 52[22–74] 31[13–56] 55[8.1–66] 0.0173 0.2722
CD8 CM 5.9[4.5–17] 14[2.8–27] 6.1[5.1–9.2] 7.8[1.0–31] 0.5531 0.4354
CD8 EM 7.0[2.9–14] 3.0[1.5–14] 4.8[1.2–17] 2.4[0.1–13] 0.0534 0.3395
CD8 TE 38[34–56] 12[6.4–26] 47[23–54] 14[4.4–35] 0.0005 0.8486
CD4+CD127+ 61[39–83] 73[53–84] 73[41–93] 68[38–85] 0.0175 0.2713
CD8+CD127+ 46[36–57] 67[56–83] 47[24–75] 60[29–76] 0.0005 0.1126
CD4+CD38+ 2.2[1.4–9.4] 6.3[4.0–15] 1.3[1.1–7.4] 2.4[0.8–4.5] 0.0143 0.0065
CD56+CD38+ 34[10–50] 17[7.2–50] 28[9.1–43] 4.1[2.8–9.0] 0.2634 0.0031
Values expressed as median[Interquartile range] of 30 subjects with pleural TB and 11 with pleural effusions caused by other diseases (non-TB); PB=peripheral blood;
PF=pleural fluid; Tregs=regulatory T cells (CD4
+CD25
+CD127
lo); Teff=effector T cells (CD4+); N=naı ¨ve; CM=central memory; EM=effector memory; TE=terminal
effector.
doi:10.1371/journal.pone.0030324.t002
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We performed 27-plex cytokine analysis on unstimulated
pleural fluid to determine which marker(s) could best predict
pleural TB. A high level of IFN-c has previously been seen in un-
manipulated pleural fluid samples from TB patients in South
Africa [16]. In the present study IFN-c levels .1171 pg/mL
resulted in a high degree of sensitivity and specificity and 88%
correct classification of pleural effusions caused by TB or not
(p=0.0003; Fig. 3 and Table 3). We also found a number of
other markers that accurately discriminated between TB and non-
TB in unstimulated pleural fluid. These included significantly
higher levels of Eotaxin (p=0.0243), IL-10 (p=0.0034), IL-13
(p=0.0025), IL-6 (p=0.0005) and IP-10 (p=0.0004) in subjects
with TB compared to those without (Fig. 3). Logistic regression
analysis showed that levels of IP-10 .36,695 pg/mL could
discriminate between subjects with TB and those without with a
specificity of 82% and sensitivity of 85% (AUC of 0.84) (Fig. 3
and Table 3). This was slightly lower than IFN-c but IP-10
resulted in the best likelihood ratio (positive and negative=9.6 and
0.1 respectively compared to positive LR of 2.8 for IFN-c; data not
shown). Levels of IL-6 .23,254 pg/mL resulted in a sensitivity of
93% but a comparatively low specificity (64%; Table 3). IL-10
was 100% sensitive but again, low in specificity (64%) at levels
.17 pg/mL. Multivariate analysis showed that a combination of
IL-6, IL-10 and IP-10 increased the AUC to 0.96 (Table 3), with
the positive likelihood ratio increasing to 10.
Figure 2. Quantitative and qualitative analysis of PPD-specific T cell responses. (a) Qualitative IFN-c and TNF-a responses following
overnight antigen stimulation of peripheral blood or pleural fluid cells. Shown are representative flow cytometry profiles from a patient with definite
TB following overnight stimulation with anti-CD3/CD28 (positive control), ESAT-6/CFP-10 fusion protein (EC), PPD or unstimulated (media alone). (b)
Quantitative assessment of IFN-c, IL-2 and TNF-a secreting CD4+ T cells in subjects with TB and those without. Shown are the proportions of CD4+ T
cells in the PF secreting IFN-c, IL-2 or TNF-a in response to overnight stimulation with PPD. Statistical analysis was performed using a Mann-Whitney U
test and p-values,0.05 were considered statistically significant (indicated). (c) Relative levels of polyfunctional T cell responses in subjects with TB or
without. Shown are pie graphs demonstrating the proportion of cytokine-positive CD4+ T cells that produced only 1 of the cytokines (white), any 2 of
the cytokines (black) or all 3 cytokines (red) from blood or pleural fluid of subjects with or without TB following anti-CD3/CD28, EC or PPD stimulation
overnight. Statistical analysis of overall variance was performed using in-built SPICE software (ANOVA) and p-values indicate significantly decreased
polyfunctionality compared to cells from the pleural fluid of subjects with TB. (d) Analysis of the functional profile of PPD-specific CD4+ T cells on the
basis of simultaneous production of IFN-c, IL-2 and TNF-a. All possible combinations of the 3 cytokines are shown along the y-axis. Statistical analysis
was performed using a Mann-Whitney U- test and p-values are indicated (Pleural fluid TB significantly different to all 3 other groups).
doi:10.1371/journal.pone.0030324.g002
Figure 3. Multiplex cytokine analysis of ex vivo pleural fluid samples. Pleural fluid from subjects with TB (n=27) and subjects without TB
(n=11) was assessed for 27 different cytokines using a Bioplex multi-cytokine analyser. Results are shown for IFN-c, Eotaxin, IL-10, IL-13, IL6 and IP-10
levels in unstimulated fluid. Statistical analysis was performed using logistic regression analysis with Stata 3 software and multiple comparisons
corrected for using Bonferonni’s correction. Significance was set at p,0.05 and are indicated. Red dots indicate HIV-positive subjects.
doi:10.1371/journal.pone.0030324.g003
Diagnosis of Pleural TB
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30324Discussion
In this study we show that the immune profile in the pleural
fluid is distinct from the peripheral blood in subjects with pleural
TB illustrating the sequestration of effector cells to the site of
infection at this acute stage of disease. Importantly, we have
determined both cellular and soluble biomarkers in the pleural
fluid that can easily discriminate between pleural effusions caused
by TB and those caused by other diseases such as pneumonia or
malignancy. These findings provide valuable insight into TB
pathogenesis and, once validated in a larger cohort, will aid in the
development of new and improved TB diagnostics.
The first aim of this study was to determine if the peripheral
blood is representative of what is occurring in the lung during
pleural TB. We found it was very distinct presumably reflecting of
the sequestration of CD4+ effector cells to the lungs during this
acute stage of disease. Indeed, the proportion of CD4+ T cells in
the pleural fluid was significantly increased in TB patients and had
a memory phenotype compared to the blood of the same patients
or blood and pleural fluid of the non-TB patients. Treg cells were
also increased in the pleural fluid compared to blood of TB
patients however this was synchronous with the increase in effector
CD4+ T cells such that the ratio of Treg to Teff cells was not
significantly different; in keeping with their immunomodulatory
role in protecting against excessive inflammation that is associated
with an increase in effector T cells. This finding suggests that Treg
increases should always be assessed alongside CD4+ Teff cells. The
second aim of this study was to determine if peripheral blood cells
could provide a surrogate biomarker for pleural TB if pleural
effusions could not be obtained. However, having analysed over 40
subsets of cells, the only differences we saw between TB and non-
TB patients were an increase in CD8+ T cells and CD56+ NK
cells; most likely non-specific.
Supporting our findings on the response of cells to antigen
stimulation, a recent paper showed high levels of polyfunctional T
cells with an effector memory phenotype in subjects with pleural
TB [10], whilst PPD-specific responses in the BAL have been
shown to be significantly higher in pulmonary and extrapulmo-
nary TB patients compared to non-tuberculous control subjects
[12]. However, few studies have directly compared the blood and
lung responses from the same subjects. Surprisingly, we saw a
significantly lower response to antigenic stimulation from periph-
eral blood cells compared to the pleural fluid cells, presumably due
to sequestration of the effector memory population to the site of
infection. Indeed, analysis of the PPD-responsive cells in the
pleural fluid resulted in 95% correct classification of TB disease or
not. Cellular analysis of the pleural effusions also allowed us to
diagnose other underlying causes, particularly malignancies, and
was also applicable for analysis of ascites fluid. Our results indicate
that use of blood-based diagnostics may be inaccurate at this acute
stage of disease and possibly accounts for the reduced sensitivity
for active TB disease with the current IFN-c release assays
(IGRAs) [17]. We believe flow cytometry should be included in a
diagnostic algorithm for extrapulmonary TB where feasible;
however its use as a rapid diagnostic test is limited in resource-
poor settings.
Therefore, the final aim of this study was to determine soluble
biomarkers for pleural TB, which presents the most viable option
for development of a field-friendly, rapid diagnostic test. Previous
studies have found high levels of IFN-c in ex vivo pleural fluid [16]
with a recent meta-analysis showing close to 100% specificity and
sensitivity for pleural TB [18]. However, we found much lower
sensitivity using IFN-c alone in our study despite the relatively
high levels in unstimulated fluid, presumably reflecting genetic
differences in the study sites. Alongside IFN-c, we found high
levels of IP-10 and IL-6 with a combination of IP-10, IL-6 and IL-
10 resulting in 96% correct classification of pleural TB. IP-10 is
primarily (but not solely) induced by IFN-c (with enhanced
production seen with dual TNF-a and IFN-c stimulation [19]) and
is a potent chemo-attractant for activated T cells [19]. It has
previously been shown to be elevated in tuberculous pleurisy
[19,20], although the discriminatory power compared to IFN-c for
both pulmonary and pleural TB appears to be variable [19–23].
IL-6 has also been shown to be increased in pleural TB [11], is
important in the pro-inflammatory response and has recently been
shown to be one of the most important biomarkers in TB,
alongside IP-10 and IL-10 [24].
In conclusion, this study defines both cellular and soluble
biomarkers that provide high levels of sensitivity and specificity for
pleural TB in a West African cohort. Whilst cellular biomarkers
are currently not applicable for generation of a rapid diagnostic
test, the use of flow cytometry as part of the diagnostic algorithm
for extrapulmonary TB is important where feasible. However, a
combination of soluble biomarkers (IP-10, IL-10 and IL-6),
resulted in high specificity and sensitivity for pleural TB, were
not affected by HIV status and, once validated, hold great promise
for development of a rapid diagnostic test for pleural TB.
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